Tox21 is a collaborative effort to improve methods scientists use to evaluate potential toxicity of environmental chemicals and medicines.
Read about how NIH and its partners are advancing treatments for rare lipid disorders, activities planned for NIH's Rare Disease Day, improving CTSA-funded research protocols, and more.
NIH researchers are collaborating with Vtesse, Inc., to develop treatments for Niemann-Pick disease type C and other rare lysosomal storage disorders.
A team of researchers from NCATS and the Icahn School of Medicine at Mount Sinai identified more than 50 drugs that may block Ebola virus-like particles from entering and infecting cells.
How is NCATS advancing translational research? Learn more about the Center's work and some of its early successes.
MORE CENTER NEWS
NCATS screening technologies enable identification of potential treatment target for neurological disorder.
Researchers support projects aimed at finding treatments for diabetic keratopathy.
- NCATS Announces Tox21 Data Challenge Winners • NCATS
- Drug Activates Brown Fat and Increases Metabolism • NIH Research Matters
- Brown Fat May Protect against Diabetes and Obesity • NHS Choices
- More News & Events...